Cisplatinum in Combination with 5-Fluorouracil and Citrovorum Factor in the Treatment of Advanced Colorectal Carcinoma

References

• Sugarbaker P H, McDonald J S, Gunderson L L. Colorectal cancer. Principles and Practice of Oncology, VT DeVita, S Hellman, SA Rosenberg. JB Lippincott, Philadelphia 1982; 868
   Google Scholar
• Abbruzzese J L. Recent approaches to the systemic therapy of advanced colorectal carcinoma. Cancer Bull 1988; 40: 238–243
   Google Scholar
• Grem J L, Hoth D F, Hamilton J M. Overview of current CDDP with 5-FU and CF for Colorectal Carcinoma status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep 1987; 71: 1249–1263
   PubMedGoogle Scholar
• Grem J L, King S A, O'Dwyer P J. Biochemistry and clinical activity of JV-(phosphonacetyl)-L-aspartate: a review. Cancer Res 1988; 48: 4441–4454
   PubMed Web of Science ®Google Scholar
• Moran G. Leucovorin enhancement of the effects of the fluoro-pyrimidines on thymidylate synthase. Cancer 1989; 63: 1008–1012
   PubMed Web of Science ®Google Scholar
• Rustum Y M. Toxicity and antitumor activity of 5-fluorouracil in combination with leucovin. Cancer 1989; 63: 1013–1017
   PubMed Web of Science ®Google Scholar
• Bleyer W A. New vistas for leucovorin in cancer chemotherapy. Cancer 1989; 63: 995–1007
   PubMed Web of Science ®Google Scholar
• Waxman S, Bruckner H. The enhancement of 5-fluorouracil an-timetabolic activity by leucovorin, menadione and alpha-toco-pheraol. Eur J Cancer Clin Oncol 1982; 18: 685–692
   PubMedGoogle Scholar
• Santi D V, McHenry C S, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974; 13: 471–481
   PubMed Web of Science ®Google Scholar
• Danenberg P V, Danenberg K D. Effect of 5,10-methylenetetra-hydrofolate on the dissociation of 5-fluoro-2′-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry 1978; 17: 4018–4124
   PubMed Web of Science ®Google Scholar
• Lockshin A, Danenberg P V. Biochemical factors affecting the tightness of 5-fluorodeoxyurydylate binding to human thymidylate synthetase. Biochem Pharmacol 1981; 30: 247–257
   PubMed Web of Science ®Google Scholar
• Ullman B, Lee M, Martin D W. Cytotoxicity of 5-fluoro-2′-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci USA 1978; 75: 980–983
   PubMed Web of Science ®Google Scholar
• Mini E, Moroson B A, Bertino J R. Cytotoxicity of floxuridine and 5-fluorouracil in human T-lymphoblast leukemia cells: enhancement by leucovorin. Cancer Treat Rep 1987; 71: 381–389
   PubMedGoogle Scholar
• Keyomarsi K, Moan R G. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 1986; 46: 5229–5235
   PubMed Web of Science ®Google Scholar
• Yin M B, Zakrzewski S F, Hakala M T. Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 1983; 23: 190–197
   PubMed Web of Science ®Google Scholar
• Evans R M, Laskin J D, Hakala M T. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 1981; 41: 3288–3295
   PubMed Web of Science ®Google Scholar
• Houghton J A, Maroda S J, Phillips J O. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinoma in vivo. Cancer Res 1981; 41: 144–149
   PubMed Web of Science ®Google Scholar
• Nadal J C, Van Ordeningen C J, Pinedo H M. In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma. Biomed Pharmacother 1988; 42: 387–393
   PubMed Web of Science ®Google Scholar
• Creaven P J. 5-Fluorouracil and folinic acid: summary of clinical experience. International Symposium on the Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy, Rustum Y, McGuire J. Plenum Press, New York 1988; 303–311
   Google Scholar
• Arbuck G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 1989; 63: 1036–1044
   PubMed Web of Science ®Google Scholar
• Kovach J S, Moertel C G, Schutt A J. Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel. Cancer Chemother Rep 1973; 57: 357–359
   PubMedGoogle Scholar
• De Simone P A, Davita E, Jochimsen P R. High dose cisplatin in the treatment of advanced adenocarcinoma of the colon and rectum: a Southeastern cancer study group trials. Cancer Treat Rep 1986; 70: 1229–1230
   PubMedGoogle Scholar
• Schabel F M, Trader M W, Laster W R. Cw-dichlorodiam-minoplatinum: combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63: 1459–1464
   PubMedGoogle Scholar
• Scanlon K J, Newman E M, Lu Y. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986; 83: 8923–8925
   PubMed Web of Science ®Google Scholar
• Kish J A, Weaver A, Jacobs J. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984; 53: 1824–1828
   Google Scholar
• Palmeri S, Gebbia V, Russo A. Cisdiamminodichloropla-tinum plus 5-day continuous infusion of 5-fluorouracil in the treatment of locally recurrent and metastatic head and neck cancer patients. J Cancer Res Clin Oncol 1989; 115: 579–582
   PubMed Web of Science ®Google Scholar
• Trave F, Rustum Y M, Goranson J. Synergistic antitumor activity of cw-platin and 5-fluorouracil (5Fura) in mice bearing leukemia L1210 cells. Proc AARC 1985; 26: 322
   Google Scholar
• Palmeri S, Trave F, Goranson J. Basis for the therapeutic efficacy of cisplatin (DDP) and 5-fluorouracil (FURA) alone and in combination against mouse leukemia L1210 cells. 14th International Cancer Congress, Budapest, Aug 21–27, 1986. Vol 3: 937
   Google Scholar
• Palmeri S, Trave F, Russello O, Rustum Y. The role of drug sequence in therapeutic selectivity of the combination of 5-fluorouracil and c/s-platin. Select Cancer Ther 1989; 5: 169–177
   PubMedGoogle Scholar
• Pratesi G, Gianni L, Monzotti C. Sequence dependence of the antitumor and toxicity effects of 5-fluorouracil and ew-diam-minedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol 1988; 21: 237–240
   PubMed Web of Science ®Google Scholar
• Palmeri S, Gebbia V, Russo A. A phase I study of cisplatin (CDDP) in modulation with 5-fluorouracil (5-FU) and citrovorum factor (CF) in advanced colorectal cancer (CRC). EORTC Symposium on Advances in Gastrointestinal Tract Cancer Research and Treatment, Strasbourg, Nov 15–17, 1989, 95
   Google Scholar
• Palmeri S, Gebbia V, Russo A. Oral tegafur in the treatment of gastrointestinal tract cancers: a phase II study. Br J Cancer 1990; 61: 475–478
   PubMed Web of Science ®Google Scholar
• Erlichman C, Fine S, Wong A. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1988; 6: 469–475
   PubMed Web of Science ®Google Scholar
• Doroshow J H, Bertrand M, Multhauf P. Prospective randomized trial comparing 5-FU versus 5-FU and high dose folinic acid for treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol 1987; 6: 96
   Google Scholar
• Petrelli N, Herrera L, Rustum Y. A prospective randomized trial of 5-FU versus 5-FU and high dose leucovorin versus 5-FU and MTX in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559–1565
   PubMed Web of Science ®Google Scholar
• O'Connell M J. A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Cancer 1989; 63: 1026–1030
   PubMed Web of Science ®Google Scholar
• Nobile M T, Mg Vidili, Sobrero A. 5-Fluorouracil (5-FU) alone or combined with high dose folinic acid (FA) in advanced colorectal cancer patients: a randomized trial. Proc Am Soc Clin Oncol 1988; 7: 97
   Google Scholar
• Loehrer P J, Turner S, Kubils P. A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group Trial. J Clin Oncol 1988; 6: 642–648
   PubMed Web of Science ®Google Scholar
• Madajewicz S, Avvento L. Clinical trials with 5-FU, folinic acid and cisplatin in patients with gastrointestinal malignances. J Chemother 1990; 2: 33–37, (Suppl l)
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Depisch D, Schiessel R. Phase II evaluation of 5-fluorouracil, folinic acid and cisplatin in advanced stage colorectal adenocarcinoma. Oncology 1989; 46: 217
   PubMed Web of Science ®Google Scholar
• Leong L, Doroshow J, Akman S. Phase II trial of 5-FU and high dose folinic acid (HDFA) with c/s-platin (CDDP) and dypiridamole (DP) in advanced colorectal cancer. Proc Am Soc Clin Oncol 1989; 8: 99
   Google Scholar
• Chiarion V, Figoli F, Gulisano M. 120 hours 5-fluorouracil (%FU) continuous infusion (c.i.) plus cisplatin (p) and folinic Palmed et al. acid (F) in metastatic colon cancer (M.C.C.). Proc Am Soc Clin Oncol 1988; 7: 109
   Google Scholar
• Madajewicz S, Burk M, Dainer P. Continuous infusion (CI) of 5-fluorouracil (5-FU) and cw-platin (DDP) for metastatic colorectal cancer (MCRC) and other gastrointestinal malignances. Proc Am Soc Clin Oncol 1988; 29: 800
   Google Scholar
• Zaniboni A, Zambruni A, Marpicati P. Treatment of advanced colorectal and gastric cancer with m-platinum and fluo-rouracil: a pilot study. Chemioterapia 1986; 5: 347
   PubMedGoogle Scholar
• Madajewicz S, Avvento L. Clinical trials with 5-fluorouracil, folinic acid and cisplatin in patients with gastrointestinal malignances. J Chemother 1990; 2: 33, (Suppl 1)
   PubMed Web of Science ®Google Scholar